Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Personalis, Inc.
PSNL
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $1.2B
$13.62
▼ -1.23%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$3.84 - $14.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 83.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary NeXT Platform with integrated tumor and immune microenvironment analysis from minimal samples
- Advanced neoantigen prediction capabilities (NeXT SHERPA and NeXT NEOPS) for personalized cancer vaccines
- Strategic partnerships with Mayo Clinic and leading biopharmaceutical companies providing market validation
- Comprehensive data analytics combining genomics with AI for actionable clinical and research insights
- Liquid biopsy technology enabling non-invasive, real-time tumor monitoring for patient management
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Moderate growth ahead
Expanding adoption of precision oncology and personalized medicine in cancer treatment
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+109.6% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PSNL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 7, 2026
Reported EPS of -$0.29 vs -$0.23 consensus (-26.1% surprise). Revenue of $15.5M vs $14.5M expected (+6.8%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-26.1%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
-15%
+6%
-24%
-44%
+3%
-25%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$22.6M
$25.7M
$16.8M
$20.6M
$17.2M
$14.5M
$17.3M
$15.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-194.1%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$10.00
▼ -26.6% vs $13.62
Latest: Morgan Stanley · $9.00 · May 12, 2026
2 analysts covering